Ariad Pharmaceuticals said patient enrollment for a late-stage trial of Iclusig, or ponatinib, in patients with newly diagnosed chronic myeloid leukemia is now halfway complete. Based on an interim analysis, Ariad said it could potentially submit Iclusig for U.S. approval as a first-line treatment in 2014's third quarter, half a year sooner than expected.

Related Summaries